Skip to main content
Fig. 1 | BMC Hematology

Fig. 1

From: Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

Fig. 1

AZA-MDS-003 study design. ECOG PS, Eastern Cooperative Oncology Group performance status; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndromes; PD, progressive disease; RBC, red blood cell; Tx, treatment. a Unblinding will occur after all randomized patients have received ≥ 12 months of Tx or have discontinued from the study, whichever occurs first

Back to article page

BMC Hematology

ISSN: 2052-1839

Contact us